Arrowstreet Capital
RYTM icon

Arrowstreet Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Arrowstreet Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,307
Closed -$637K – 2000
2025
Q3 		$637K Buy
+6,307
New +$586K ﹤0.01% 1668

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital's RYTM Position: Q4 2025 in Review

Arrowstreet Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 6,307 shares — an estimated $637K sold.

Arrowstreet Capital first reported a position in RYTM in Q3 2025 and held it in 1 quarter. The position peaked at $637K in Q3 2025. 280 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Arrowstreet Capital reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 6,307 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $637K.
  • Arrowstreet Capital first reported a position in Rhythm Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Arrowstreet Capital's Rhythm Pharmaceuticals position peaked at $637K in Q3 2025.
  • 280 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Arrowstreet Capital's 13F filing for Q4 2025, filed 13 Feb 2026.